

Parameter Statistic	Treatment Group Comparisons									
	Sparsentan, Pooled (200 mg, 400 mg, and 800 mg) to Irbesartan 300 mg		Sparsentan, Pooled (400 mg and 800 mg) to Irbesartan 300 mg		Sparsentan 400 mg to Irbesartan 300 mg		Sparsentan 800 mg to Irbesartan 300 mg		Sparsentan 200 mg to Irbesartan 300 mg	
	Irbesartan (n=32)	Sparsentan (n=64)	Irbesartan (n=25)	Sparsentan (n=51)	Irbesartan (n=17)	Sparsentan (n=21)	Irbesartan (n=8)	Sparsentan (n=30)	Irbesartan (n=7)	Sparsentan (n=13)
Baseline UP/C (g/g)										
n	32	64	25	51	17	21	8	30	7	13
Mean	4.017	4.707	3.816	4.824	3.482	4.749	4.526	4.876	4.734	4.248
(SD)	(2.6717)	(3.7810)	(2.7160)	(4.0506)	(2.6074)	(4.1696)	(2.9842)	(4.0362)	(2.5701)	(2.5304)
Median	3.265	3.620	2.970	3.530	2.850	3.710	3.295	3.225	4.860	3.710
Min, Max	0.88, 10.73	0.43, 18.66	0.88, 10.73	0.43, 18.66	1.10, 10.73	1.25, 18.66	0.88, 9.76	0.43, 14.68	0.98, 8.03	1.50, 10.15
Week 8 UP/C (g/g)										
n	32	64	25	51	17	21	8	30	7	13
Mean	3.164	3.300	2.990	3.208	2.795	2.452	3.405	3.737	3.786	3.663
(SD)	(2.2713)	(3.5719)	(2.3598)	(3.4738)	(2.4581)	(2.6254)	(2.2343)	(3.9177)	(1.9501)	(4.0650)
Median	2.405	1.980	2.390	1.900	2.380	1.730	3.020	2.085	3.640	2.060
Min, Max	0.43, 10.19	0.12, 14.47	0.43, 10.19	0.12, 14.47	0.43, 10.19	0.28, 12.34	1.11, 8.37	0.12, 14.47	1.45, 6.69	0.59, 14.38
Percentage Change from Baseline to Week 8 (95% CI) ^a	-18.5 (-34.6, 1.7)	-44.8 (-52.7, -35.7)	-19.0 (-38.0, 5.9)	-47.4 (-56.3, -36.9)	-28.1 (-47.5, -1.6)	-52.7 (-64.3, -37.2)	-9.3 (-45.3, 50.3)	-41.3 (-54.4, -24.4)	-15.0 (-41.8, 24.2)	-33.1 (-49.3, -11.6)
Ratio (sparsentan/ irbesartan) ^b (95% CI)		0.7 (0.5, 0.9)		0.6 (0.5, 0.9)		0.7 (0.4, 1.0)		0.6 (0.4, 1.1)		0.8 0.5, 1.3
p-value ^c	---	0.006	---	0.011	---	0.056 ^d	---	0.127 ^d	---	0.298 ^d

Abbreviations: ANCOVA = analysis of covariance; CI = confidence interval; LS = least squares; Max = maximum; Min = minimum; SD = standard deviation; UP/C = urine protein to creatinine ratio ; UPE = urinary protein excretion

- a Geometric least squares mean, calculated as $[\exp(\text{LS mean change from baseline in natural log(UP/C)}) - 1] \times 100$. The same transformation was applied to obtain the corresponding 95% CI.
- b Ratio (sparsentan/irbesartan) = $\exp[\text{LS mean change from baseline in natural log(UPE) for sparsentan} - \text{LS mean change from baseline in natural log(UPE) for irbesartan}]$. The same transformation is applied to obtain corresponding 95% CI for the ratio (sparsentan/irbesartan).
- c p-value is the treatment effect p-value from the ANCOVA model. An ANCOVA model was fitted with the change in natural log(UP/C) from baseline as the dependent variable, treatment and cohort as the main effects, and baseline natural log(UP/C) as a covariate.
- d Nominal p-value.

Source: Table 14.2.1.1.1 15AUG2019; Table 14.2.1.2.1 15AUG2019; Table 14.2.1.3.1 15AUG2019; Table 14.2.1.4.1 15AUG2019; Table 14.2.1.5.1 15AUG2019